Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Completed · Phase 3 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder (ADHD)

In brief

The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.

Key facts

Study ID

NCT03325881

Run by

Shire

People needed

89

Starts

2017-12-09

Expected to finish

2018-06-07

Last updated by the study team

2021-06-02

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant is male or female aged 6-12 years inclusive at the time of consent.
• Participant's parent or legally authorized representative (LAR) must provide signature of informed consent, and there must be documentation of assent (as applicable) by the participant.
• Participant must meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a primary diagnosis of ADHD (any subtype).
• Participant who is a female and of child-bearing potential must not be pregnant and agree to comply with any applicable contraceptive requirements.
• Participant has an ADHD-RS-5 Child, Home Version Total Score of greater than or equal to (>=) 28 and Clinical Global Impression - Severity of Illness (CGI-S) score >=4 at baseline (Visit 2). Participant is currently not on ADHD therapy, or is not completely satisfied with their current ADHD therapy.

You may not qualify if…

• Participant is required or anticipated to take medications that have central nervous system effects or affect performance. Stable use of bronchodilator inhalers is not exclusionary.
• Participant has a concurrent chronic or acute illness, disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the participant.
• Participant has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
• Participant has failed to fully respond, based on investigator judgment, to an adequate course of amphetamine therapy.
• Participant has a known family history of sudden cardiac death or ventricular arrhythmia.
• Participant has a blood pressure measurement >=95th percentile for age, sex, and height at screening (Visit 1) and/or baseline (Visit 2).
• Participant has a height less than or equal to (<=) 5th percentile for age and sex at screening (Visit 1) or baseline (Visit 2).
• Participant has a weight <=5th percentile for age and sex at screening (Visit 1) or baseline (Visit 2).
• Participant has a known history of symptomatic cardiovascular disease, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac conditions placing them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
• Participant has a history of seizures (other than infantile febrile seizures).
• Participant is taking any medication that is excluded per the protocol.
• Participant had any clinically significant ECG or clinical laboratory abnormalities at the screening (Visit 1) or baseline visit (Visit 2).
• Participant has current abnormal thyroid function, defined as abnormal thyroid-stimulating hormone and thyroxine at the screening or baseline visit. Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
• Participant has a current, controlled (requiring medication or therapy) or uncontrolled, comorbid psychiatric disorder.
• Participant is currently considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or has a prior history of or currently demonstrating suicidal ideation.

Where it is running

• Harmonex Neuroscience Research — Dothan, Alabama, United States
• PEWMD, PA, ARCSM, PLLC, PRP, Inc. — Little Rock, Arkansas, United States
• Advanced Research Center — Anaheim, California, United States
• Riverside Medical Clinic — Riverside, California, United States
• Peninsula Research Associates - CRN — Rolling Hills, California, United States
• Care Research Center — Doral, Florida, United States
• Power MD Clinical Research Institute — Hialeah, Florida, United States
• Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida, United States
• Acevedo Medical Group — Miami, Florida, United States
• Pharmacology Research, LLC — Miami, Florida, United States
• Scientific Clinical Research Inc. — North Miami, Florida, United States
• Clinical Neuroscience Solutions, Inc. — Orlando, Florida, United States
• Clinical Associates of Orlando, Llc — Orlando, Florida, United States
• GA Psychiatric Services, LLC. — Atlanta, Georgia, United States
• Buford Family Practice — Buford, Georgia, United States
• One Health Research Clinic, Inc. — Norcross, Georgia, United States
• Institute for Behavioral Medicine — Smyrna, Georgia, United States
• Advanced Clinical Research Inc. — Meridian, Idaho, United States
• Conventions Psychiatry and Counseling — Naperville, Illinois, United States
• Pedia Research, LLC — Evansville, Indiana, United States
• Psychiatric Associates — Overland Park, Kansas, United States
• Kentucky Pediatric/Adult Research — Bardstown, Kentucky, United States
• Pedia Research, LLC — Owensboro, Kentucky, United States
• Neuroscientific Insights — Rockville, Maryland, United States
• Neurobehavioral Medicine Group — Bloomfield Hills, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.